NASHVILLE, Tenn. - Taking a cue from the Fosamax jaw injury multidistrict litigation, plaintiffs in the Aredia/Zometa MDL on Sept. 10 asked the court to stay discovery and remand 313 cases for trial, saying defendant Novartis Pharmaceuticals Corp. is "gaming" the MDL to delay resolution for plaintiffs who are dying of cancer on an almost weekly basis while waiting for the seven-year-old litigation to move toward trial (In Re: Aredia and Zometa Products Liability Litigation, MDL Docket No. 1760, No. 3:06-md-1760, M.D. Tenn., Nashville Div.).